BIVI
Price
$8.05
Change
-$0.42 (-4.96%)
Updated
Jul 9 closing price
Capitalization
14.95M
XENE
Price
$32.68
Change
+$1.26 (+4.01%)
Updated
Jul 9 closing price
Capitalization
2.51B
28 days until earnings call
Interact to see
Advertisement

BIVI vs XENE

Header iconBIVI vs XENE Comparison
Open Charts BIVI vs XENEBanner chart's image
BioVie
Price$8.05
Change-$0.42 (-4.96%)
Volume$94.46K
Capitalization14.95M
Xenon Pharmaceuticals
Price$32.68
Change+$1.26 (+4.01%)
Volume$1.26M
Capitalization2.51B
BIVI vs XENE Comparison Chart in %
Loading...
BIVI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BIVI vs. XENE commentary
Jul 10, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIVI is a Hold and XENE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 10, 2025
Stock price -- (BIVI: $8.05 vs. XENE: $32.68)
Brand notoriety: BIVI and XENE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BIVI: 30% vs. XENE: 91%
Market capitalization -- BIVI: $14.95M vs. XENE: $2.51B
BIVI [@Biotechnology] is valued at $14.95M. XENE’s [@Biotechnology] market capitalization is $2.51B. The market cap for tickers in the [@Biotechnology] industry ranges from $314.48B to $0. The average market capitalization across the [@Biotechnology] industry is $2.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BIVI’s FA Score shows that 1 FA rating(s) are green whileXENE’s FA Score has 1 green FA rating(s).

  • BIVI’s FA Score: 1 green, 4 red.
  • XENE’s FA Score: 1 green, 4 red.
According to our system of comparison, XENE is a better buy in the long-term than BIVI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BIVI’s TA Score shows that 5 TA indicator(s) are bullish while XENE’s TA Score has 6 bullish TA indicator(s).

  • BIVI’s TA Score: 5 bullish, 5 bearish.
  • XENE’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, XENE is a better buy in the short-term than BIVI.

Price Growth

BIVI (@Biotechnology) experienced а -17.04% price change this week, while XENE (@Biotechnology) price change was -2.07% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.70%. For the same industry, the average monthly price growth was +15.32%, and the average quarterly price growth was +17.98%.

Reported Earning Dates

BIVI is expected to report earnings on Nov 27, 2024.

XENE is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+8.70% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XENE($2.51B) has a higher market cap than BIVI($14.9M). XENE YTD gains are higher at: -16.633 vs. BIVI (-59.750). BIVI has higher annual earnings (EBITDA): -18M vs. XENE (-290.36M). XENE has more cash in the bank: 550M vs. BIVI (8.01M). BIVI has less debt than XENE: BIVI (366K) vs XENE (8.68M). XENE has higher revenues than BIVI: XENE (7.5M) vs BIVI (0).
BIVIXENEBIVI / XENE
Capitalization14.9M2.51B1%
EBITDA-18M-290.36M6%
Gain YTD-59.750-16.633359%
P/E RatioN/AN/A-
Revenue07.5M-
Total Cash8.01M550M1%
Total Debt366K8.68M4%
FUNDAMENTALS RATINGS
BIVI vs XENE: Fundamental Ratings
BIVI
XENE
OUTLOOK RATING
1..100
5882
VALUATION
overvalued / fair valued / undervalued
1..100
13
Undervalued
75
Overvalued
PROFIT vs RISK RATING
1..100
10043
SMR RATING
1..100
9895
PRICE GROWTH RATING
1..100
6578
P/E GROWTH RATING
1..100
1005
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BIVI's Valuation (13) in the null industry is somewhat better than the same rating for XENE (75) in the Biotechnology industry. This means that BIVI’s stock grew somewhat faster than XENE’s over the last 12 months.

XENE's Profit vs Risk Rating (43) in the Biotechnology industry is somewhat better than the same rating for BIVI (100) in the null industry. This means that XENE’s stock grew somewhat faster than BIVI’s over the last 12 months.

XENE's SMR Rating (95) in the Biotechnology industry is in the same range as BIVI (98) in the null industry. This means that XENE’s stock grew similarly to BIVI’s over the last 12 months.

BIVI's Price Growth Rating (65) in the null industry is in the same range as XENE (78) in the Biotechnology industry. This means that BIVI’s stock grew similarly to XENE’s over the last 12 months.

XENE's P/E Growth Rating (5) in the Biotechnology industry is significantly better than the same rating for BIVI (100) in the null industry. This means that XENE’s stock grew significantly faster than BIVI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BIVIXENE
RSI
ODDS (%)
Bullish Trend 1 day ago
85%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
79%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
77%
MACD
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 3 days ago
72%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
74%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
74%
Advances
ODDS (%)
Bullish Trend 9 days ago
83%
Bullish Trend 14 days ago
72%
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 3 days ago
75%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
85%
Bearish Trend 1 day ago
83%
Aroon
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
BIVI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CVM2.800.36
+14.75%
Cel-Sci Corp
YETI32.280.35
+1.10%
YETI Holdings
IIIN38.890.32
+0.83%
Insteel Industries
CDW180.750.10
+0.06%
CDW Corp
ENTA7.13-0.62
-8.00%
Enanta Pharmaceuticals

BIVI and

Correlation & Price change

A.I.dvisor indicates that over the last year, BIVI has been loosely correlated with HURA. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if BIVI jumps, then HURA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIVI
1D Price
Change %
BIVI100%
-4.96%
HURA - BIVI
47%
Loosely correlated
+0.40%
HOFBF - BIVI
44%
Loosely correlated
N/A
SCNI - BIVI
34%
Loosely correlated
+4.47%
BIORQ - BIVI
34%
Loosely correlated
+29.75%
XENE - BIVI
27%
Poorly correlated
+4.01%
More

XENE and

Correlation & Price change

A.I.dvisor indicates that over the last year, XENE has been loosely correlated with IDYA. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if XENE jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XENE
1D Price
Change %
XENE100%
+4.01%
IDYA - XENE
55%
Loosely correlated
+7.09%
CRNX - XENE
54%
Loosely correlated
+10.08%
ATXS - XENE
53%
Loosely correlated
+5.62%
NRIX - XENE
51%
Loosely correlated
+7.94%
IONS - XENE
50%
Loosely correlated
+3.60%
More